CERC - Cerecor trades higher as FDA accepts IND application for CERC-007

Cerecor ([[CERC]] +5.8%) announced that its Investigational New Drug Application to study the use of CERC-007 to treat Still’s disease has been accepted by the FDA and is now open.CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb).The first study will be a global multi-centre Phase 1b clinical trial in adult onset Still’s disease and is planned to start in Q1 2021 and the initial data is expected in the Q2 2021.Previously: Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma (Dec. 16)

For further details see:

Cerecor trades higher as FDA accepts IND application for CERC-007